The NeurologyLive® MS Disease Spotlight page offers specific updates and coverage on the latest expert conversations and data readouts related to the treatment and management of patients with multiple sclerosis and demyelinating disorders.
July 25th 2024
Tiziana Life Sciences’ intranasal foralumab has shown potential in treating nonactive secondary progressive multiple sclerosis through innovative immune modulation.
Importance of Telehealth Services for the MS Population
Published: July 5th 2024 | Updated: July 10th 2024Bryant Robinson, senior manager of government relations at the National MS Society, discussed how telehealth access has become vital for patients with multiple sclerosis who often lack nearby specialist care.
The Challenge of Treating Fatigue in Multiple Sclerosis: Anthony Feinstein, MPhil, PhD, FRCP
May 31st 2024The professor of psychiatry at the University of Toronto discussed the various medications for multiple sclerosis fatigue that have been tested but ultimately fail to outperform placebo. [WATCH TIME: 4 minutes]
Challenges and Potential of BTK Inhibitors in MS Treatment: Bruce Cree, MD, PhD, MAS, FAAN
May 30th 2024The clinical research director of the UCSF Multiple Sclerosis Center talked about results from clinical trials assessing BTK inhibitors in relapsing multiple sclerosis and the ongoing research to explore more effective treatments. [WATCH TIME: 5 minutes]
Understanding Silent Progression in Multiple Sclerosis: Bruce Cree, MD, PhD, MAS, FAAN
May 29th 2024The clinical research director of the UCSF Multiple Sclerosis Center discussed the early-onset progression in multiple sclerosis and emphasized the need for targeted therapies in this patient population. [WATCH TIME: 6 minutes]
Pregnancy and Infant Outcomes Remain Unchanged With Multiple Sclerosis Therapy Ocrelizumab
Published: May 29th 2024 | Updated: May 29th 2024Overall, the results mirrored previous reports demonstrating that patients on ocrelizumab before or during pregnancy did not have elevated risk of adverse pregnancy and infant outcomes.
Future Directions and Takeaways Regarding Anti-CD20 Therapies in MS
May 20th 2024Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, share perspectives on the future of MS care, the importance of vigilance in lab testing, and why patients may need reassurance about the potential for disease control with currently available therapies.
Open-Label Data vs Real-World Data for Anti-CD20 Therapies in Multiple Sclerosis
May 14th 2024Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, discuss the utility of real-world data, particularly when it comes to understanding subtle differences between agents from both a safety and efficacy perspective.
A Call to Action to Address Disparities in Multiple Sclerosis Care: Jaime Imitola, MD
Published: May 6th 2024 | Updated: May 6th 2024The chief of the Division of MS and Neuroimmunology at UConn Health talked about the challenges with access to care in multiple sclerosis, particularly for marginalized communities, despite significant progress made in the field over the past decades. [WATCH TIME: 4 minutes]
FDA Allows Additional Enrollment to Foralumab Expanded Access Program
May 4th 2024To date, treatment with foralumab has shown promising results in stabilizing or improving clinical measures without serious adverse effects among patients with non-active secondary progressive multiple sclerosis.
The Importance of Lifestyle Changes in Multiple Sclerosis Care
April 29th 2024Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, review the benefits of exercise and physical activity in patients with MS. They also discuss strategies for talking to patients about the positive effects of lifestyle changes.